Contemporary progress in ovarian cancer screening

Current Oncology Reports

Volumn 9, Issue 6, 2007, Pages 485-493

  Walsh, Christine S ^a   Karlan, Beth Y ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 72-4 ANTIGEN; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; OSTEOPONTIN; PREALBUMIN; PROLACTIN; PROSTASIN; SOMATOMEDIN B; VASCULOTROPIN;

ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARIECTOMY; OVARY CANCER; PATIENT SELECTION; PREDICTION; PREVALENCE; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRANSVAGINAL ECHOGRAPHY;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MASS SCREENING; NEOPLASM STAGING; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 36049042527     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0068-2     Document Type: Review

References (51)

1. Holschneider CH, Berek JS: Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000, 19:3-10.
2. Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG: Enthusiasm for cancer screening in the United States. JAMA 2004, 291:71-78.
3. Brawley OW, Kramer BS: Cancer screening in theory and in practice. J Clin Oncol 2005, 23:293-300.
4. Wilson JMG, Junger G: Principles and Practice of Screening for Disease. Public Health Papers. Geneva: World Health Organization; 1968.
5. Goff BA, Mandel L, Muntz HG, Melancon CH: Ovarian carcinoma diagnosis. Cancer 2000, 89:2068-2075.
6. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004, 3:355-366.
7. Hogg R, Friedlander M: Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004, 22:1315-1327.
8. Berchuck A, Iversen ES, Lancaster JM, et al.: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005, 11:3686-3696.
9. Horiuchi A, Itoh K, Shimizu M, et al.: Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol Oncol 2003, 88:309-317.
10. Bell DA, Scully RE: Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994, 73:1859-1864.
11. Campbell S, Bhan V, Royston P, et al.: Transabdominal ultrasound screening for early ovarian cancer. BMJ 1989, 299:1363-1367.
12. Timmerman D, Testa AC, Bourne T, et al.: Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol 2005, 23:8794-8801.
13. Ueland FR, DePriest PD, Pavlik EJ, et al.: Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol 2003, 91:46-50.
14. Alcazar JL, Merce LT, Laparte C, et al.: A new scoring system to differentiate benign from malignant adnexal masses. Am J Obstet Gynecol 2003, 188:685-692.
15. van Nagell JR Jr, DePriest PD, Reedy MB, et al.: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000, 77:350-356.
16. Fishman DA, Cohen L, Blank SV, et al.: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005, 192:1214-1221; discussion 1221-1212.
17. Liede A, Karlan BY, Baldwin RL, et al.: Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 2002, 20:1570-1577.
18. Bast RC Jr, Feeney M, Lazarus H, et al.: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68:1331-1337.
19. Woolas RP, Xu FJ, Jacobs IJ, et al.: Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993, 85:1748-1751.
20. Moss EL, Hollingworth J, Reynolds TM: The role of CA125 in clinical practice. J Clin Pathol 2005, 58:308-312
21. Jacobs IJ, Skates SJ, MacDonald N, et al.: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999, 353:1207-1210.
22. Skates SJ, Menon U, MacDonald N, et al.: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003, 21:206-210.
23. Menon U, Skates SJ, Lewis S, et al.: Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005, 23:7919-7926.
24. Buys SS, Partridge E, Greene MH, et al.: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005, 193:1630-1639.
25. Rosenthal AN, Menon U, Jacobs IJ: Screening for ovarian cancer. Clin Obstet Gynecol 2006, 49:433-447.
26. Rosen DG, Wang L, Atkinson JN, et al.: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005, 99:267-277.
27. Bast RC Jr: Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003, 21:200-205.
28. Rapkiewicz AV, Espina V, Petricoin EF III, Liotta LA: Biomarkers of ovarian tumours. Eur J Cancer 2004, 40:2604-2612.
29. McIntosh MW, Urban N, Karlan B: Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev 2002, 11:159-166.
30. Meri S, Baumann M: Proteomics: posttranslational modifications, immune responses and current analytical tools. Biomol Eng 2001, 18:213-220.
31. Mok SC, Chao J, Skates S, et al.: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001, 93:1458-1464.
32. Draghici S, Chatterjee M, Tainsky MA: Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. Expert Rev Mol Diagn 2005, 5:735-743.
33. Posadas EM, Davidson B, Kohn EC: Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr Opin Oncol 2004, 16:478-484.
34. Sellers TA, Yates JR: Review of proteomics with applications to genetic epidemiology. Genet Epidemiol 2003, 24:83-98.
35. Petricoin EF, Ardekani AM, Hitt BA, et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
36. Sorace JM, Zhan M: A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003, 4:24.
37. Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004, 96:353-356.
38. Kozak KR, Amneus MW, Pusey SM, et al.: Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 2003, 100:12343-12348.
39. Zhang Z, Bast RC Jr, Yu Y, et al.: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64:5882-5890.
40. Kozak KR, Su F, Whitelegge JP, et al.: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5:4589-4596.
41. Ye B, Cramer DW, Skates SJ, et al.: Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003, 9:2904-2911.
42. Mor G, Visintin I, Lai Y, et al.: Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005, 102:7677-7682.
43. Ness RB, Grisso JA, Klapper J, et al.: Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 2000, 152:233-241.
44. Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616-1622.
45. van Nagell JR Jr, Gallion HH, Pavlik EJ, DePriest PD: Ovarian cancer screening. Cancer 1995, 76:2086-2091.
46. Vuento MH, Pirhonen JP, Makinen JI, et al.: Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 1995, 76:1214-1218.
47. Sato S, Yokoyama Y, Sakamoto T, et al.: Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 2000, 89:582-588.
48. Einhorn N, Sjovall K, Knapp RC, et al.: Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992, 80:14-18.
49. Grover S, Quinn MA, Weideman P, et al.: Screening for ovarian cancer using serum CA125 and vaginal examination: report on 2550 females. Int J Gynecol Cancer 1995, 5:291-295.
50. Skates SJ, Horick N, Yu Y, et al.: Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004, 22:4059-4066.
51. Gorelik E, Landsittel DP, Marrangoni AM, et al.: Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:981-987.